Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
Licogliflozin (LIK066) is a non-anti-fibrotic treatment agent for non-alcoholic steatohepatitis (NASH).
[1]. Monica A. Konerman, et al. Overview of Clinical Treatment Trials for NASH.Curr Hepatol Rep. 2017 Dec;16(4): 366-373.
















